Diabetes: Part 2 Flashcards

1
Q

Common Insulin Regimens
 Type 1
(2)

A

◦ Basal-Bolus
◦ Insulin Pump (with or without CGM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Common Insulin Regimens
 Type 2 (typically 2nd or 3rd line agent)
(3)

A

◦ Basal with oral agents (metformin/others)
◦ Basal-Bolus (with or without metformin/other oral agents)
◦ Basal with Glucagon Like Peptide-1 Receptor Agonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Questions:
 RK is a 38-year-old patient with diabetes who comes to your office for a
routine cleaning and 6 month check up. He is taking the following
medications: insulin aspart, insulin glargine, metformin and
rosuvastatin.
 TRUE OR FALSE?
◦ RK’s is likely to have the diagnosis of type 1 diabetes
 Why or why not?
 Which insulin is RK using as his bolus insulin?
 Which insulin is RK using as his basal insulin?
 Which one of his medications is most likely to cause hypoglycemia?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Management of Hypoglycemia
 Rule of 15
 Treat if < 70 mg/dl
(5)

A
  • 15-20 gms fast acting carbs = 3-4
    glucose tablets, 4 oz juice or
    regular soda, 5 lifesavers, 3
    peppermints
  • Glucose gel also available – follow
    directions on tube
  • If next meal is more than 1 hr away
    consider a small snack to prevent
    recurrence
  • Observe patient 30-60 mins after
    recovery. Confirm normal glucose
    level before patient allowed to
    leave
  • Consider referring patient to
    physician for follow up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Management of Hypoglycemia
 Unconscious patient or unable to swallow
(6)

A

◦ Call 911 (have someone call or if alone call after administering 1st dose of glucagon)
◦ Stimulates gluconeogenesis - release of stored glucose ( glycogen) from the liver.
◦ 1mg glucagon intravenously or intramuscularly in buttock, arm or thigh (may give IM at almost
any body site if necessary). Repeat at 15 minutes if no response
◦ 0.5 mg for pediatrics < 44 lbs
 Patient needs glucose after injection
◦ OR, give 50ml of 50% dextrose IV
 Turn on side to prevent aspiration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Common Agents Used in T2DM

A

 Metformin
 Glucagon-like peptide-receptor agonists (GLP1-RA)
◦ end in “tide” – exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide
 Glucagon-like, peptide-1 (GLP-1) agonist and glucose-dependent
insulinotropic polypeptide (GIP) agonist (a “twincretin”)
 also ends in “tide”- tirzepatide
 Sodium glucose cotransporter-2 inhibitors (SGLT-2)
◦ “flozins” - canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
 Dipeptidyl-Peptidase-4 Inhibitors (DPP-4)
◦ “gliptins” – sitagliptin, saxagliptin, linagliptin, alogliptin
 Thiazolidinedione (TZD)
◦ “glitazones” – pioglitazone, rosiglitazone
 Sulfonylureas
◦ Start with ”g” and end in “ide” - glipizide, glyburide, glimepiride
 Others (less common)
◦ Meglitinides – “litinides”- repaglinide, netaglinide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

 Which oral agents are most likely to cause
hypoglycemia?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Questions
 Which medication’s primary mechanism of action
decreases the production of glucose (gluconeogenesis) in
the liver?
a. empagliflozin
b. glipizide
c. liraglutide
d. metformin

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pharmacologic Therapy for Adults With Type 2 Diabetes
PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT
9.8 Healthy lifestyle behaviors, diabetes self-management education and support,
avoidance of therapeutic inertia, and social determinants of health should be
considered in the glucose-lowering management of type 2 diabetes. A
9.9 A person-centered shared decision-making approach should guide the choice of
pharmacologic agents for adults with type 2 diabetes. Consider the effects on

9.10 The glucose-lowering treatment plan should consider approaches that support
weight management goals (Fig. 9.3 and Table 9.2) for adults with type 2 diabetes. A

A

cardiovascular and renal comorbidities; effectiveness; hypoglycemia risk; impact
on weight, cost, and access; risk for adverse reactions and tolerability; and
individual preferences (Fig. 9.3 and Table 9.2).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pharmacologic Therapy for Adults With Type 2 Diabetes (continued)
PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT
9.17 In adults with type 2 diabetes who have not achieved their individualized weight
goals, additional weight management interventions (e.g., intensification of lifestyle
modifications, structured weight management programs, pharmacologic agents, or
metabolic surgery, as appropriate) are recommended. A
9.18 In adults with type 2 diabetes and …

A

established or high risk of atherosclerotic
cardiovascular disease, heart failure (HF), and/or chronic kidney disease (CKD), the
treatment plan should include agent(s) that reduce cardiovascular and kidney disease
risk (e.g., sodium-glucose cotransporter 2 inhibitor [SGLT2] and/or glucagon-like
peptide 1 receptor agonist [GLP-1 RA]) (Fig. 9.3, Table 9.2, Table 10.3B, and Table 10.3C)
for glycemic management and comprehensive cardiovascular risk reduction,
independent of A1C and in consideration of person-specific factors (Fig. 9.3) (see
Section 10, “Cardiovascular Disease and Risk Management,” for details on cardiovascular
risk reduction recommendations).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DM Goals – Risk Reduction Strategies
 Reduce the risk of —
complications through glycemic control and controlling co-morbid
conditions to which DM contributes

A

macrovascular and microvascular (and other)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

◦ Reduce cardiovascular and renal risk factors
(3)

◦ Reduce the risk of vaccine-preventable diseases
(1)

 Minimize periodontal complications due to diabetes mellitus,
provide safe and effective dental care, and promote good oral
health

A

 Control BP
 Control Lipids
 Smoking Cessation

 Immunizations
 Examples: Flu, Tdap/Td, Pneumococcal, Hepatitis B (others)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MACROVASCULAR COMPLICATIONS
 Atherosclerotic cardiovascular disease (ASCVD)

A

◦ is the leading cause of morbidity and mortality for individuals with diabetes and is the largest
contributor to the direct and indirect costs of diabetes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

 Consistent — control to goal directly affects reduction of macrovascular
complications

A

glycemic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ABCS to prevent Heart Attack, Stroke and Peripheral Arterial Disease

A

◦ Aspirin (low dose) if indicated (based on CV risk)
- Primary prevention – only high risk
- Secondary prevention – YES! (indicated)
◦ Blood pressure control
 Common antihypertensives:
- Thiazide diuretics
- ACE inhibitors (”prils”)
- Angiotensin II inhibitors (“sartans”)
- Others
◦ Cholesterol control
- “Statins”
◦ Smoking cessation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Microvascular Complications
(4)

A

 Optimize Blood Pressure and Glycemic control to prevent complications
 Diabetic Kidney Disease
 Diabetic Retinopathy
 Neuropathies - Diabetic Peripheral Neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

 Diabetic Kidney Disease
(4)

A

◦ Renal dose dosing adjustments
◦ Treatment
 ACE Inhibitor or Angiotensin Receptor Blocker (ARB)
 Added benefit from SLGT2s (preferred to minimize renal complications) and GLP1RAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

 Diabetic Retinopathy
(2)

A

◦ Diminished vision – may impact patient reading prescriptions or written information
◦ Treatment from an ophthalmologist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

 Neuropathies - Diabetic Peripheral Neuropathy
(2)

A

◦ Common non-opioid adjuvants such as antidepressants and anticonvulsants
 Common side effects - xerostomia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Having DM increases the risk of

A

infection, more serious infections/ infectious complications and slows healing/recovery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Parameter: Influenza- indicated for all > 6 months of
age including DM patients
Recommendation/Comments

A

Annually (all patients > 6 months)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Parameter: Specific recommendations for DM - Pneumococcal
vaccines
Recommendation/Comments

A

NEWER options: PCV 20 (Prevnar 20) or PCV 15 (Vaxneuvance)
with PPSV-23 (Pneumovax) 1 year later

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Parameter: Hepatitis B - indicated for all adults including
DM patients if no prior history
Recommendation/Comments

A

Complete series for those 19-59 years if no previous history
of receipt
>60 years with DM if no history of receipt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Parameter: Tdap/Td – all adults
Recommendation/Comments

A

At least 1 Tdap then Every 10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Parameter: Recombinant Zoster Vaccine (RZV – Shingrix) Recommendation/Comments
2 doses adults > 50 years old
26
Parameter: Respiratory Syncytial Virus (RSV) - Recommendation/Comments
1 dose > 60 years or older
27
Dental implications of patients with DM  Identifying the patient with undiagnosed diabetes: (4)
◦ What diabetic symptoms might the patient exhibit from a dental exam? ◦ If suspect, refer patient to primary care provider  Stress importance of diagnosis (especially early diagnosis)  Minimize long-term complications
28
Diabetes mellitus is one of the strongest systemic risk factors for --- disease
periodontal
29
Both T1DM and T2DM increase the risk of periodontal disease -- fold
3-4
30
 Diabetes mellitus is one of the strongest systemic risk factors for periodontal disease  Both T1DM and T2DM increase the risk of periodontal disease 3-4 fold (4)
 Control of DM may affect the extent and severity of periodontal disease  Poorly controlled DM may increase the risk of periodontal disease, tooth decay/ dental caries and dental infections (bacterial and fungal)  Chronic hyperglycemia may create host hyper-inflammatory response  Oral infections can increase risk of hyperglycemia in DM patients
31
 Chronic hyperglycemia may create host hyper-inflammatory response (5)
◦ Diminished neutrophil recruitment and function ◦ More severe inflammatory response - increases production of pro-inflammatory cytokines and chemokines due to:  Direct activation of several pro-inflammatory pathways  oxidative stress  endothelial dysfunction.
32
Recognizing Undiagnosed Diabetes  Undiagnosed patients may not notice subtle symptoms or relate them to DM – dental exam may be particularly valuable for identifying suspicion of T2DM  Dental exam may reveal possible oral manifestations of pre-DM/DM: (list)  Consider referring to health care provider for DM screening
◦ Candidiasis or other less common alterations in normal flora ◦ Periodontitis - bleeding gums, gingival inflammation ◦ Tooth mobility ◦ Acetone breath - fruity smelling breath (more likely with T1DM) ◦ Recurrent, acute or chronic gingival and periodontal infections and abscesses ◦ Suppuration ◦ Xerostomia ◦ Increased salivary viscosity/flow ◦ Enlargement of parotid glands (alteration in basement membrane) ◦ Oral burning sensation ◦ Angular cheilosis ◦ Acanthosis nigricans (skin condition that causes thickened, velvety, dark discoloration in body folds – commonly seen on neck) – sign of insulin resistance ◦ Increased rate of dental caries ◦ Poor wound healing ◦ Note: these clinical signs may be caused by other underlying issues, unrelated to diabetes, but undiagnosed diabetes should be considered
33
Screening in Dental Practice (3)
 A recent study estimated about 30% of patients ages 30 years and older, who were seen in general dental practices had hyperglycemia.  The utility of chairside oral screening to determine the need, as well as, have the ability to refer a patient with potential DM to primary care could improve the diagnosis, and therefore treatment of prediabetes and diabetes and ultimately decrease/ minimize periodontal disease.  More extensive research is needed to demonstrate the feasibility, effectiveness and cost-effectiveness of screening in this setting
34
Asking a Patient about Diabetes Management (7)
 What type of diabetes do you have, and when was it diagnosed? ◦ May be able to determine by patient’s medication  Have you been experiencing any issues related to your diabetes?  Are you taking all of the medications that have been prescribed for you? If not, which one(s) don’t you take and why?  Have you taken your diabetes medication today?  What is your most recent A1C level? When was the last A1C taken?  How often do you check your blood glucose level, and what was the most recent value? What have your values ranged over the last few weeks?
35
Questions to ask patients with diabetes (6)
 Tell me about your carbohydrate intake (do you watch your consumption?). What time did you last eat? What did you consume? (This question will give you hints about how well-educated the patient is about their disease and may be important to discuss if dental problems impact a patient’s eating or how diet impacts oral health.)  What health care providers help you manage your diabetes? Do you see your physician, nurse, or dietitian, other diabetes specialist on a regular basis? When was your last visit? Does anyone at home help you manage your diabetes day to day? (with medications, following a diet, etc.)  Do you experience low blood sugar levels? If so, how often? What are your symptoms? When was your last event? What do you do when you have low blood sugar?  Do you smoke or use any tobacco products? If so, how much?  What are your blood sugars running at home?  Others....
36
Dental management considerations for patient with diabetes (4)
 In patients with controlled DM, no special treatment is required for routine dentistry  Morning visits may be preferred – lower insulin activity and/or an appointment after a meal or snack for patients with history of hypoglycemia  For routine visits – patient with DM should eat normally and take usual medications prior to the visit IMPORTANT TO CONFIRM THIS BEFORE PROCEDING WITH THE VISIT  If patient needs to be fasting for invasive procedure/treatment and is not eating, or is not eating normally due to dental pain, the patient may need to hold/or adjust diabetes medications Usually only hold those that cause hypoglycemia (consult with diabetes provider, if needed)
37
Dental management considerations for patient with diabetes, continued
 Complete a Medical History to identify patients with diabetes What type of DM does the patient have? How does the diagnosis impact the DM medications you might see on the patient’s medication list?  Assess current glycemic control ◦ Glucose levels/A1c - if known  Is patient using a CGM? ◦ Ask if patient currently experiencing any signs/symptoms of hypoglycemia ◦ Frequency of hypoglycemic episodes? ◦ Medication evaluation  What common diabetes medications might you see in this patient?  Because of increased risk of hypertension, important to check BP (whether diagnosed with hypertension or not – provide recommendations for follow-up/referral if concerned)
38
Dental Treatment/Procedures  Random blood glucose values: ◦ Generally, between --- mg/dl for elective dental procedures ◦ Check with office --- or ask patients to bring their monitor or get CGM readings and obtain value prior to invasive treatment ◦ The patient’s meter or CGM application will likely have a memory where trends can be assessed, if needed ◦ --- appointments – consider additional checks  Relying on the patient’s memory to provide accurate values is risky (2)
70-200 glucometer Long ◦ May not remember accurately or don’t know ◦ May be too embarrassed or “fudge” better number to not admit poor control
39
Dental management considerations, continued  During invasive treatments or procedures, addressing: ◦ Most common complication – --- ◦ ALSO, be aware of risks of ---, especially ketoacidosis in type 1  presentation similar to hypoglycemia in a conscious patient –  Consider appropriate treatment of anxiety and/or pain (stress/pain may increase cortisol and epinephrine secretion which can precipitate hyperglycemia)  Best way to determine hypo- or hyper- glycemia is to ...
hypoglycemia hyperglycemia blurry vision, difficulty concentrating, increased urination, fatigue, extreme thirst, dry mouth, dizziness, headache, nausea/vomiting, confusion, (others). check a blood sugar but symptoms can trigger suspicion
40
Dental management considerations, continued If patient is hypoglycemic when checking blood glucose prior to/during dental interventions: Follow Rule of 15s (4)
Once glucose is above 70 mg/dl have patient consume a snack and recheck blood glucose before proceeding with a dental intervention (or reschedule) Long appointments – recheck glucose (may need additional carbohydrates) Check reading at end of appointment to be sure patient is safe to leave office At conclusion of the appointment, the patient should be advised to eat a meal or an additional small snack if next meal is more than 1 hr to prevent recurrence
41
If Identify Diabetic Related Medical Issues/Concerns/Complications (3)
 Determine if issue warrants immediate or urgent medical attention before elective dental procedures  Refer patient to diabetes provider or ask when patient has the next scheduled visit for less urgent issue  Patients with uncontrolled hyperglycemia may be candidates for prophylactic antibiotic therapy or longer antibiotic therapy for infection.
42
Best Practices for Managing Insulin Pumps during Ambulatory Dental Procedures/Surgery (5)
 Dependent on the specific manufacturer and type of pump being utilized  Develop a clear management plan with the patient that includes how the pump will be managed intraoperatively, especially in the event of hypoglycemia or hyperglycemia  A signed consent from the patient/guardian to continue pump use throughout the perioperative period - recommended  Recommend patient position pump at a site at least 24 hours prior to surgery to minimize problems, such as cannula occlusion or erratic absorption, and to allow time to verify correct functioning of the pump and any accompanying CGM system, if present  Assess the patient’s blood sugar preoperatively, at regular intervals during the procedure and prior to discharge
43
Basal Rate Management No universal management strategy for determining or adjusting the basal infusion rate intraoperatively, Consider consulting with the health care team managing the patient’s diabetes for recommendations Patient should stop bolus insulin while NPO but continue normal basal preoperatively Generally, 2 options for managing the basal rate of insulin delivery during surgery
◦1) maintain the normal basal infusion rate ◦2) reduce the basal rate, commonly down to 80% of normal ◦Additional option: some pump systems will have an exercise rate, which is a reduced infusion rate to account for higher glucose demands during periods of increased physical exertion; this option can be selected  A lower infusion rate during the procedure can alleviate the potential for perioperative hypoglycemia Perioperative hypoglycemia can be managed with exogenous dextrose even without making changes to the continuous pump system’s basal rate ◦IV dextrose should be available ◦Typically, maintaining the basal insulin rate and correcting any hypoglycemia with IV dextrose is often the common plan Balance hypoglycemia risk with commonly observed intraoperative hyperglycemia - the body tends to be in a relative state of insulin deficiency
44
Insulin Pump Management  Patients on pump therapy (DM patient, in general) should be ideally scheduled for early morning appointments to minimize potential for ...  Patient should provide a demonstration of ..., if present prior to the procedure ◦ ENSURE UNDERSTANDING OF HOW TO TURN THE PUMP --- IN CASE OF HYPOGLYCEMIA ◦ Keep in mind that slow absorption of insulin from the infusion site will cause the effects of the basal infusion to persist for up to -- hours after stopping the infusion.
hypoglycemia or hyperglycemia insulin pump controls and the CGM OFF 2
45
Questions for Pump Operation  Key Functional Controls of Insulin Pumps to Understand (7)
◦ How to check the blood glucose using the CGM? ◦ How to check normal functioning of the pump’s basal infusion? ◦ How to manually stop or turn off the pump? ◦ Is there a sensor augmented function that will deliver insulin at a set blood glucose? ◦ Is there a threshold suspend mechanism that will stop the pump at a set blood glucose? ◦ How to manually deliver a bolus of insulin if required? ◦ What types of alarms are on the pump or CGM?
46
Hypoglycemic unawareness (6)
 Individuals with long standing Type 1 DM are at greatest risk  Can occur with Type 2 DM  The counter-regulatory systems of glucagon and epinephrine secretion which cause symptoms such as palpitations and tremors to not be triggered in some patients with long-standing use of exogenous insulin  Can also arise due to diabetes neuropathy blunting the effects mediated by the autonomic nervous system in response to hypoglycemia.  The brain may become desensitized to the symptoms of hypoglycemia as it becomes "used to" low blood sugar levels.  Beta-blockers (cardiovascular medications ending in “olol” or “ilol” such as metoprolol, carvedilol, etc.) can mask signs and symptoms of hypoglycemia (except sweating)
47
Dental Emergency Kits (2)
 Glucose – tablets/gel  Glucagon
48
 Glucagon (5)
◦ ** Special note for alpha-glucosidase inhibitors** ◦ Acarbose (Precose) and miglitol (Glyset) ◦ Don’t cause hypoglycemia as monotherapy but are often prescribed with other antidiabetic medications that do ◦ If patient becomes hypoglycemic and is taking acarbose or miglitol only use oral glucose or lactose (yogurt or low/nonfat milk) or glucagon if severe to treat hypoglycemia ◦ Alpha-glucosidase inhibitors will block absorption of other sugars
49
Hyperglycemia Avoid hyperglycemia – blood glucose levels < --- mg/dl before initiating any invasive dental treatments Stress from dental procedures and/or dental inflammation/infections may cause increased --- levels
200 glucose
50
Stress from dental procedures and/or dental inflammation/infections may cause increased glucose levels (3)
Increase endogenous catecholamine secretion = increase heart rate, blood pressure, and blood glucose levels from stress/infection/inflammation Uncontrolled DM can cause increased healing time and put patient at higher risk of infection Stress reduction techniques or shorter appointments may help minimize a rise in glucose from stress
51
Considerations for dental management for patients with diabetes (4)
Use of vasoconstrictors in local anesthetics Use of corticosteroids can increase glucose and cause hyperglycemia Assess patients for infections and delayed/poor wound healing Avoid elective and complex procedures in patients with poorly controlled diabetes (> 200 mg/dl)
52
Use of vasoconstrictors in local anesthetics (4)
* Epinephrine stimulates hepatic glucose production and inhibits of glucose uptake by insulin-dependent tissues which may lead to hyperglycemia * Routine use of local anesthetic with 1:100,000 epinephrine is generally well tolerated in DM patients
53
Assess patients for infections and delayed/poor wound healing * Patients with diabetes are at increased risk, especially if their diabetes is
poorly controlled
54
How could the complications of diabetes impact dental care?  Decreased --- acuity (from microvascular complications and/or poor glucose control) ◦ may make self examination of mouth and performance of oral hygiene difficult ◦ challenges reading directions on prescription bottles or other printed information  --- disease can affect drug metabolism for drugs metabolized by the kidney ◦ adjustment of the dosages of antibiotics or analgesics (or avoidance of NSAIDs in patients with GFR < 30ml/min) may be required.  If the patient is on a daily aspirin for CV risk, patients may bleed more easily  Diabetes and diabetic medications may cause --- changes
visual Renal xerostomia/taste
55
Education and Follow-up  Patients with diabetes should be strongly encouraged to maintain a good oral hygiene: (4)  Educate about dental risks with DM (2) health  Encourage smoking cessation for oral and CV health (1)  Dental visits q 6 months
◦ brushing after every meal ◦ using floss daily ◦ keeping dentures clean ◦ saliva substitutes for severe xerostomia ◦ Patients don’t typically receive education on the impact of DM on oral cavity in formal DM education programs ◦ Importance of normalizing blood glucose = improved oral health, which ultimately effects overall ◦ Compounded risks with smoking and DM to oral health
56
Post procedure/op considerations  Prophylaxis/treatment of infection, when appropriate  Proper dietary intake (5)  Proper anti-diabetic drug therapy (5)
◦ If the patient is expected to have difficulty in eating solid food after dental procedure, diet should be modified to soft solids or liquids ◦ Keep carbohydrate intake consistent ◦ Consult diabetes provider or dietician for post-op diet plan, if appropriate ◦ Using a blender or lower carbohydrate liquid meal replacement (Glucerna) may be an option ◦ Maintain adequate hydration ◦ Consider if meal-time insulin therapy needs to be adjusted for changes in eating ◦ Consider if rapid/fast acting insulin or insulin secretors/secretagogues should be decreased or held until patient resumes full meals ◦ Consider adjustments in other medications (not usually necessary) ◦ In some cases, glucocorticoids, stress from procedure, infection, inflammation and/or delayed healing may warrant closer monitoring of blood glucose and temporarily adjustment (increases) in diabetic therapies ◦ Consult with diabetes provider for plan for post-op drug therapy, if appropriate
57
Diabetes Self-Management and Education  Diabetes self-management and education is important aspect for treatment plan  Requires the expertise of a variety of healthcare professionals including dental professionals (2)  Recognize relationship between diabetes and depression (2)  Communicate relationship between diabetes and macrovascular/microvascular complications
◦ Dental professionals can become Certified Diabetes Educators (The National Certification Board for Diabetes Educators – NBCDE)  Promotes self-management to achieve individualized behavioral and treatment goas that optimize health outcomes ◦ Poorer glucose control and oral hygiene ◦ Referral to primary care or mental health provider
58
Management of Xerostomia and Oral Candidiasis  Common oral complications of DM – decreases --- production  Most common contributors of --- in pts with DM - xerostomia and possibly poor glycemic control ◦ Associated with decreased salivary gland function due to ---  DM affects the nerves that control --- ◦ DM may cause structural changes to --- glands ◦ Some studies show independent of poor glycemic control
saliva candidiasis autonomic neuropathy salivary gland secretion parotid
59
Management of Xerostomia and Oral Candidiasis  Most common manifestation is chronic atrophic (erythematous) candidiasis (3)
◦ Red or velvet textured plaques ◦ May complain of burning sensation or taste alterations ◦ Smokers and denture wearers with poor oral hygiene at greater risk
60
SP’s insulin glargine is best classified as a: a. rapid-acting insulin b. short-acting insulin c. intermediate-acting insulin d. long-acting insulin
61
Management of Xerostomia and Oral Candidiasis  Treatment (4)
◦ Topical antifungal agents for candidiasis  Usually, topical administration (nystatin, others) is effective, unless the infection is severe, then systemic agents (fluconazole) may be indicated ◦ Xerostomia - treatment with salivary stimulants, artificial saliva/saliva substitutes, sipping water/non-caffeine- free, sugar-free drinks, use of sugar-free chewing gum, etc. to minimize symptoms ◦ Topical fluoride interventions for patients with high caries rate
62
Which of SP’s medications is most likely to cause hypoglycemia? a. metformin b. dapagliflozin c. insulin glargine d. lisinopril
63
What is the mechanism of action for dapagliflozin? a. works in the kidneys to block the reabsorption of glucose b. works in the liver to decrease gluconeogenesis c. works in the pancreas to stimulate beta cells to release insulin d. works in the muscles to increase glucose uptake by enhancing the effectiveness of endogenous insulin